
Intralesional interleukin-2 immunotherapy produced an 81% complete response rate with only mild adverse events in patients with high-risk #SquamousCellCarcinoma not eligible for surgery.
ja.ma/3NP2Z08

English
JAMA Dermatology
14.8K posts

@JAMADerm
JAMA Dermatology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.







































